Shortridge Dee, Castanheira Mariana, Pfaller Michael A, Flamm Robert K
JMI Laboratories, North Liberty, Iowa, USA
JMI Laboratories, North Liberty, Iowa, USA.
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00465-17. Print 2017 Jul.
The activity of ceftolozane-tazobactam was compared to the activities of 7 antimicrobials against 3,851 isolates collected from 32 U.S. hospitals in the Program to Assess Ceftolozane-Tazobactam Susceptibility from 2012 to 2015. Ceftolozane-tazobactam and comparator susceptibilities were determined using the CLSI broth microdilution method at a central monitoring laboratory. For ceftolozane-tazobactam, 97.0% of the isolates were susceptible. Susceptibilities of the other antibacterials tested were: amikacin, 96.9%; cefepime, 85.9%; ceftazidime, 85.1%; colistin, 99.2%; levofloxacin, 76.6%; meropenem, 81.8%; and piperacillin-tazobactam, 80.4%. Of the 699 (18.1%) meropenem-nonsusceptible isolates, 87.6% were susceptible to ceftolozane-tazobactam. Six hundred seven isolates (15.8%) were classified as multidrug resistant (MDR), and 363 (9.4%) were classified as extensively drug resistant (XDR). Only 1 isolate was considered pandrug resistant, which was resistant to all tested agents, including colistin. Of the 607 MDR isolates, 84.9% were ceftolozane-tazobactam susceptible, and 76.9% of XDR isolates were ceftolozane-tazobactam susceptible. activity against drug-resistant indicates ceftolozane-tazobactam may be an important agent in treating serious bacterial infections.
在2012年至2015年的头孢洛扎/他唑巴坦敏感性评估项目中，将头孢洛扎/他唑巴坦的活性与7种抗菌药物对从美国32家医院收集的3851株分离菌的活性进行了比较。头孢洛扎/他唑巴坦和对照药物的敏感性在中央监测实验室采用CLSI肉汤微量稀释法测定。对于头孢洛扎/他唑巴坦，97.0%的分离菌敏感。所测试的其他抗菌药物的敏感性如下：阿米卡星，96.9%；头孢吡肟，85.9%；头孢他啶，85.1%；黏菌素，99.2%；左氧氟沙星，76.6%；美罗培南，81.8%；哌拉西林/他唑巴坦，80.4%。在699株（18.1%）对美罗培南不敏感的分离菌中，87.6%对头孢洛扎/他唑巴坦敏感。607株分离菌（15.8%）被分类为多重耐药（MDR），363株（9.4%）被分类为广泛耐药（XDR）。仅1株分离菌被认为是全耐药，对包括黏菌素在内的所有测试药物均耐药。在607株MDR分离菌中，84.9%对头孢洛扎/他唑巴坦敏感，76.9%的XDR分离菌对头孢洛扎/他唑巴坦敏感。对耐药菌的活性表明头孢洛扎/他唑巴坦可能是治疗严重细菌感染的一种重要药物。
